NeoGenomics (NASDAQ:NEO) price target increased to $11.00, issued a ratings update earlier today by First Analysis
- Updated: October 3, 2016
NeoGenomics (NASDAQ:NEO) had its target bumped up to $11.00 by First Analysis in an issued report issued 10/4/2016. The bumped up target suggests a possible upside of 0.36% based on the company's last closing price.
Yesterday NeoGenomics (NASDAQ:NEO) traded -1.76% lower at $8.08. The company’s 50-day moving average is $8.11 and its 200-day moving average is $8.09. The last stock price is down -0.12% from the 200-day moving average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Trade Volume was down over the average, with 130,592 shares of NEO changing hands under the typical 318,055
See Chart Below
NeoGenomics has with a 52 week low of $5.49 and a 52 week high of $9.54 and has a market capitalization of $0.
Also covering NeoGenomics's price target, a total of 6 firms have issued a report on the stock. The consensus target price is $9.63 with 4 equity analysts rating the company a strong buy, two firms rating the stock a buy, one analyst rating the company a hold, 0 brokerages rating the stock a underperform, and lastly zero brokerages rating the stock a sell.
General Information About NeoGenomics (NASDAQ:NEO)
NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. Its Laboratory Testing segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. The Company offers testing services, which includes Cytogenetics testing, which is the study of normal and abnormal chromosomes and their relationship to disease; fluorescence in-situ hybridization (FISH) testing, which is a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing, which is a way to measure the characteristics of cell populations, and immunohistochemistry (IHC), and digital imaging, which is a process of localizing proteins in cells of a tissue section and relies on the principle of antibodies binding specifically to antigens in biological tissues.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.